Andreas Tschirky
Medicine
Japan Analytical Industry
Japan
Biography
2014-Today VP Business Development at Hangzhou Tigermed Consulting, the biggest Clinical Contract Research Organization in China 2010-Today Co-Founder and Board Member of MAB Discovery, a start-up company with a total investment of 25 Mio. USD that develops a highly effective monoclonal antibody generation platform supporting the development of new biopharmaceutical compounds. 2010-2011 CEO of BioDuro Beijing Change agent and business driver for the company to make the company with 600+ FTEs and 45+ Mio. USD revenues more efficient and cost-effective (including full P&L responsibility). 2004-2010 General Manager of Roche R&D Center (China) ï¬ Responsible for the initiation, set up and operation of Roche’s fifth global Pharma Research Center in Shanghai with 150 FTEs and an annual budget of 24 Mio. USD. As the first non-JV multinational pharmaceutical company R&D Center, it had full access to the global information databases, focusing on Oncology, Virology and Metabolic diseases 2001-2004 R&D Head of Roche in China to prepare the setup of the first MNC R&D Hub in China 1999-2001 Roche China, Roche Basel and other Roche Research facilities, Research Coordinator for Roche in China to build a network among Academic and Research institutions in China 1997-1999 Postdoctoral position at China Pharmaceutical University at Nanjing, Department of Traditional Chinese Medicine, Complex Prescription 1996-1997 Project leader for setting up and operation of New Adler-Pharmacy at Buchs/St.Gallen 1992-1996 Assistant group leader, Paul-Scherrer Institute, ETH, coordinating interdisciplinary research projects among the Biochemistry, Immunology, Molecular Biology, Physics and Nanoscience departments 1990-1995/2000 Operational responsibility and co-ordination of off-hours hospital and commercial pharmacy services in the Basel area
Research Interest
Medicine and Pharmaceuticals
